Patent classifications
A61L27/3886
Patch graft compositions for cell engraftment
Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue. The mechanisms by which engraftment and integration of donor cells into the organ or tissue involve multiple membrane-associated and secreted forms of MMPs.
Cell preparation for extemporaneous use, useful for healing and rejuvenation in vivo
The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.
PATCH GRAFT COMPOSITIONS FOR CELL ENGRAFTMENT
Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue. The mechanisms by which engraftment and integration of donor cells into the organ or tissue involve multiple membrane-associated and secreted forms of MMPs.
BONE-LIKE PROSTHETIC IMPLANTS
A prosthetic implant comprising a biocompatible three-dimensional scaffold and at least two cell types selected from the group consisting of osteoblasts, osteoclasts, and endothelial cells or progenitors thereof.
Engineered tissue constructs
A modular engineered tissue construct includes a plurality of fused self-assembled, scaffold-free, high-density cell aggregates. At least one cell aggregate includes a plurality of cells and a plurality of biocompatible and biodegradable nanoparticles and/or microparticles that are incorporated within the cell aggregates. The nanoparticles and/or microparticles acting as a bulking agent within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate as well as to deliver bioactive agents.
Innervated artificial skin
The present invention provides, in some embodiments, multi-layer silk compositions including a first layer comprising silk fibroin and keratinocytes, a second layer comprising silk fibroin and fibroblasts, a third layer comprising silk fibroin and adipocytes, and a plurality of nervous system cells, wherein at least some of the plurality of nervous system cells span at least two layers, and methods of making and using the same. In some embodiments, provided methods and compositions further include immune cells and/or endothelial cells.
BIODEGRADABLE SCAFFOLD FOR HAIR GROWTH AND METHODS OF USE THEREFOR
Described herein are cellular scaffolds comprising a cell reservoir, a guide attached to the cell reservoir constructed from one or more biodegradable polymers, and a population of folliculo-genic cells. The cellular scaffolds are useful in growing hair.
INFUSED CARTILAGE PARTICLES
A method of making infused non-demineralized cartilage particles employs the following steps: cutting or shaving cartilage tissue into cartilage particles, washing the particles, and infusing the particles with a supernatant of biologic material or a polyampholyte cryoprotectant or a combination of both to create infused particles.
Situ expansion of engineered devices for regeneration
Engineered human tissue seed constructs are provided that are suitable for implantation in subjects. Methods of making and using the engineered tissue seed constructs are provided.
PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES ACCOMPANIED BY FIBROSIS
The present invention provides a prophylactic and/or therapeutic agent for diseases accompanied by fibrosis. A pharmaceutical composition for preventing and/or treating a disease accompanied by fibrosis in an organ and/or a tissue, which comprises a cell mixture and/or a cell condensate comprising mesenchymal cells and vascular cells (and hepatocytes, optionally). An agent capable of inhibiting organ and/or tissue fibrosis, which comprises both mesenchymal cells and vascular cells or a cell condensate thereof. By transplanting into a subject a cell mixture and/or a cell condensate comprising mesenchymal cells and vascular cells (and optionally, hepatocytes), expression levels of fibrolysis enzymes (fibrolytic factors) such as MMP1 or MMP13 are elevated, which eventually enables inhibition of fibrosis in an organ and/or a tissue, as well as prevention and/or treatment of a disease accompanied by fibrosis in an organ and/or a tissue.